To explore in a multicenter international prospective randomized study (phase III) whether rituximab combined with the standard French LMB chemotherapy scheme results in a higher rate of EFS than the LMB chemotherapy scheme alone in patients older than 18 years with Burkitt lymphoma or ALL 3.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
260
Institut Gustave Roussy
Villejuif, France
RECRUITINGEvent free survival from date of first randomization
Complete and partial response rate, overall survival, toxicity
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.